Title:Synthesis, Molecular Docking, and In vitro Antimycobacterial
Studies on N'-arylidene-4-nitrobenzohydrazides
Volume: 17
Issue: 1
Author(s): Dinesh Bhosale, Suraj N. Mali, Bapu R. Thorat*, Swati S. Wavhal, Devidas S. Bhagat and Ravikumar M. Borade
Affiliation:
- Department of Chemistry, Government of
Maharashtra, Government College of Arts and Science, Aurangabad-431001 (MS), India
Keywords:
Acid hydrazones, 4-nitrobenzohydrazide, molecular docking, 1ENY, 1TED, 2FUM.
Abstract:
Background: Mycobacterium tuberculosis (Mtb) is an organism that causes tuberculosis
(TB). In 2019, 10 million individuals worldwide contracted tuberculosis, with 1.4
million people dying from the disease each year (World Health Organization, 2021). Hydrazones-
hydrazide-based drugs have been shown to be bactericidal against M. tuberculosis
replication.
Objectives: We herein intended to synthesize a series of acid hydrazones (3a-3l) by condensing
4-nitrobenzohydrazine with substituted aromatic acids in ethanol at room temperature.
Materials and Methods: All newly synthesized compounds were characterized by standard
spectroscopic techniques. Synthesized compounds were then tested for anti-mycobacterial
activity against H37Rv strains. Molecular docking analysis was performed for three crystal
structures of 1ENY, 1TED and 2FUM Mycobacterium tuberculosis receptors.
Results: Among all tested molecules, 3i (MIC: 50 μg/mL) and 3b (MIC: 50 μg/mL) were
found to be the best ligands for further development of new anti-TB drug. We found that
our proposed molecules have higher docking scores, corresponding standard anti-TB agents,
such as ciprofloxacin and isoniazid. Synthesized compounds were found to have druglikeness
properties when tested with Lipinski’s filter for drug-likeness.
Conclusion: Our current study proposes N'-arylidene-4-nitrobenzohydrazides as anti-TB
agents. Agents with such system can be developed in future for development into active
lead molecules.